Aim: We aimed to examine the distribution and activation of peripheral T cells in TTV positive (n = 32) and negative (n = 17) hemodialyzed patients. The control group (n = 20) consisted of healthy blood donors. Method: TTV-DNA was detected by seminested PCR. CD3, CD4, CD8, CD19, CD56, CD3/HLA-DR, CD3/CD69 and the Th1/Th2 ratio of T cells were analyzed by flow cytometry. Circulating IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-13, TNF-α, TGF-β levels were measured by ELISA in the sera. Results: There was no difference between the CD3, CD4, CD8 and CD19 values of HD subjects. In addition, the expression of both activation markers, HLA-DR and CD69, was significantly elevated in the TTV-positive and -negative HD groups compared to the controls, but not showing any difference from each other. The measurements of intracellular cytokines showed the enhanced occurrence of INF-γ + CD4 T cells, and decreased appearance of IL-4 + CD4 lymphocytes in the HD groups without any significant difference between the TTV virus positive and negative patients. In addition, HD also elevated the expression of IL-10 in CD4 and CD8 (Th2) cells. There were only two significant changes in the levels of circulating cytokines: (a) IL-2 increased; (b) IL-13 decreased in both groups of HD patients compared to the controls, independently of TTV positvity or negativity. Conclusions: We assume that transfusion-transmitted virus does not cause any specific change in the distribution and activation of lymphocytes in the peripheral blood of hemodialyzed patients. Hemodialysis itself, however, results in a significant activation of peripheral T cells with the domination of increased production of Th1 type cytokines, IFN-γ, IL-2, in contrast to the decreased synthesis of Th2 type cytokines, IL-4 and IL-13. Furthermore, the increased expression of IL-10 in the CD4 and CD8 cells of HD patients can be the sign of a contraregulatory Th2 activation as an answer on the Th1 effect.

Keywords:
TTV, Lymphocytes, Cytokines, Hemodialysis
1.
Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M: A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92–97.
2.
Okamoto H, Nishizawa T, Kato N, Ukita M, Izuka H: Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 1998;10:1–16.
3.
Okamoto H, Nishizawa T, Ukita M: A novel unenveloped DNA virus (TT virus) associated with acute and chronic non A to G hepatitis. Intervirology 1999;42:196–204.
4.
Charlton M, Adjei P, Poterucha J, Zein N, Moore B, Therneau T: TT-virus infection in North America blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology 1998;28:839–842.
5.
Simmonds P, Davidson F, Lycett C, Prescott LE, Macdonald DM, Ellender J, Yap PL, Ludlam CA, Haydon GH, Gillon J, Jarvis LM: Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998;352:191.
6.
Naumov NV, Petrova EP, Thomas MG, Williams R: Prescence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998;352:195–197.
7.
Prescott LE, Simmonds P: Global distribution of transfusion-transmitted virus (letter). N Eng J Med 1998;339:776–777.
8.
Tanaka H, Okamoto H, Luengrojanakul P, Chainuvati T, Tsuda F, Tanaka T: Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non-A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. J Med Virol 1998;56:234–238.
9.
Tanaka H, Mizokami M, Orito E, Nakano T, Kato T Ding X: A new genotype of TT virus (TTV) infection among Colombian native Indians. J Med Virol 1999;57:264–268.
10.
Okamoto H, Akahane Y, Ukita M, Fukuda M, Tsuda F, Miyakawa Y: Fecal excretion of a non enveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis. J Med Virol 1998;56:128–132.
11.
Shibuya A, Satomichi A, Takeuchi A, Saigenji K, Sakurai K, Kobayashi N, Yoshida A: Transfusion transmitted virus infection in patients on maintenance haemodialysis and in hospital workers. J Hosp Infect 2001;47:277–281.
12.
Sugiyama K, Goto K, Ando T, Mizutani F, Terabe K, Kawabe Y: Prevalence of TTV DNA among children with a history of transfusion or liver disease. J Med Virol 2000;60:172–176.
13.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual., Cold Spring Harbor, Cold Spring Harbor Laboratory, 1989.
14.
Pereira BJ, Levey AS: Hepatiits C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981–999.
15.
Sarih M, Bouchrit N, Benslimane A: Different cytokine profiles of peripherial blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immun Lett 2000;74:117–120.
16.
Nagasaka A, Takahashi T, Sasaki T, Takimoto K, Miyashita K, Nakamura M, Wakahama O, Nishikawa S, Higuchi A: Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: Host genetic and virological study. J Med Virol 2001;65:52–57.
17.
Dalekos GN, Zachou K, Liaskos C: The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001;3:277–285.
18.
Lunel F, Musset L: Mixed cryoglobulinemia and hepatitis C virus infection. Minerva Med 2001;92:35–42.
19.
Lamprecht P, Moosig F, Gause A, Herlyn K, Csernok E, Hansen H, Gross WL: Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001;60:385–390.
20.
Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P: Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001;34:173–182.
21.
Pyrsopoulos NT, Reddy K: Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 2001;3:71–78.
22.
Descamps-Latscha B, Herbelin A, Nguyen AT, Roux Lambard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groete D, Jungers P: Balance between IL-1-beta, TNF-alpha and their specific inhibitors in chronic renal failure and maintenance dialysis: Relationships with activation markers of T-cells, B-cells and monocytes. J Immunol 1995;154:882–892.
23.
Takahashi C, Warrak EA, Ruzany F: Infectious endocarditis in patients on periodic hemodialysis. AMB Rev Assoc Med Bras 1991;37:119–126.
24.
Chatenoud L, Jungers P, Descamps-Latscha B: Immunological consideration of the uremic and dialyzed patient. Kidney Int 1994;45(suppl 44):592–596.
25.
Coles GA: Immunoglobulin and Complement. Contrib Nephrol. Basel, Karger, 1990, vol 85, pp 24–29.
26.
Descamps-Latscha B, Herbelin A, Nguyen AT, Jungers P, Chatenaud L: Dysregulation du systeme immunitaire chez l uremique chronique et le dialyse. Press Méd 1995;24:405–410.
27.
Pereira BJ, Shapiro L, King AJ, Falages ME, Strom JA, Dinarello CA: Plasma levels of IL-1β, TNF α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994;45:890–896.
28.
Kawanaka N, Nagake Y, Yamamura M, Makino H: Expression of Fc gamma receptor III (CD16) on monocytes during hemodialysis in patients with chronic renal failure. Nephron 2002;90:64–71.
29.
Wensky A, Marcondes MCG, Lafaille J: The role of IFN-γ in the production of Th2 subpopulations: Implications for variable Th2-mediated pathologies in autoimmunity. J Immunol 2001;167:3074–3081.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.